Abstract Poly (ADP-ribose) polymerase (PARP) is considered an essential component in
case of DNA (Deoxyribonucleic acid) damage, response by sensing DNA damage and …

Several chemotherapeutics against breast cancer are constrained by their adverse effects
and chemoresistance. The development of novel chemotherapeutics to target metastatic …

Introduction Globally, colorectal cancer (CRC) is the third most common type of cancer, and
its treatment frequently includes the utilization of drugs based on antibodies and small …

Nuclear factor kappa B (NF–κB) is a potential therapeutic target in breast cancer. In the
current study, a new class of oxazine–and piperazine–linked pyrimidines was developed as …

Small molecule-driven JNK activation has been found to induce apoptosis and paraptosis in
cancer cells. Herein pharmacological effects of synthetic oxazine (4aS, 7aS)-3-((4-(4‑chloro …

Introduction Nuclear factor kappa (NF-κB) plays a key role in cancer cell proliferation; thus,
small molecule inhibitors of NF-κB activity can effectively inhibit breast cancer (BC) …

Small molecules are being used to inhibit cyclin dependent kinase (CDK) enzymes in
cancer treatment. There is evidence that CDK is a drug-target for cancer therapy across …

Human epidermal growth factor receptor 2 (HER2)-positive breast cancer exhibits early
relapses, poor prognoses, and high recurrence rates. Herein, a JNK-targeting compound …

Breast cancer is the most common type of cancer in women. Although current treatments can
increase patient survival, they are rarely curative when the disease is advanced …

Metastasis, the dissemination of tumor cells, stands as the second most prominent
contributor to mortality arising from breast cancer. To counteract this phenomenon, the …